Mathai mammen - Latest News Update, Information, Photos & Videos on Mathai mammen at Lokmat Times

Johnson & Johnson on Thursday (local time) announced that its single-shot COVID-19 vaccine showed promising signs of protection against the Delta variant rapidly spreading across the US and other countries, in a small laboratory study.According to the company report, the vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted today to bioRxiv, a non-profit preprint server for the life sciences.The single-dose vaccine, elicited neutralising antibody activity against the Delta variant at an even higher level than what was recently observed for the Beta (B.1.351) variant in South Africa, the report stated.In the ensemble trial, Johnson & Johnson's vaccine was 85 per cent effective against severe/critical disease and demonstrated protection against hospitalisation and death. The vaccine was consistently effective across all regions studied globally, including in South Africa and Brazil, where there was a high prevalence of rapidly emerging Beta and Zeta variants during the study period."Today's newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help protect the health of people globally," said Paul Stoffels, MD, Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson."We believe that our vaccine offers durable protection against COVID-19 and elicits neutralizing activity against the Delta variant. This adds to the robust body of clinical data supporting our single-shot vaccine's ability to protect against multiple variants of concern," Stoffels added.Mathai Mammen, MD, PhD, Global Head, Janssen Research & Development, Johnson & Johnson, said: "Current data for the eight months studied so far show that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time. In addition, we observe a persistent and particularly robust, durable cellular immune response.""With each new dataset, we build on our solid foundation of evidence that our single-shot COVID-19 vaccine plays a critical role in ending the pandemic, which continues to evolve and pose new challenges to global health," Mammen said.The data showed that humoral and cellular immune responses generated by the Johnson & Johnson single-shot COVID-19 vaccine lasted through at least eight months, the latest timepoint recorded in the study thus far.The vaccine is now available in many regions and countries on a not-for-profit basis during the emergency pandemic period. It received emergency use authorisation (EUA) in the United States on February 27 and Conditional Marketing Authorization (CMA) by the European Commission on March 11.( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Home

City

Latest News

Cricket

LT Premium

National

International

Maharashtra

Opinions

Chhatrapati Sambhajinagar

Nagpur

Entertainment

Photos

Business

Technology

Sports

Lifestyle

Social Viral

Lokmat Games

Health

Pahalgam Terror Attack

Tahawwur Rana

IPL 2025

CM Devendra Fadnavis

Mumbai Local

Weather Update

Mathai Mammen, NewsFOLLOW

Mathai mammen, Latest News

International :J&J's single-dose COVID-19 vaccine shows promising signs against Delta variant

Johnson & Johnson on Thursday (local time) announced that its single-shot COVID-19 vaccine showed promising signs of protection against the Delta variant rapidly spreading across the US and other countries, in a small laboratory study. ...